Target ALS

At Target ALS, we’ve identified three major scientific barriers to progress: 🔬 Biological complexity 💊 Drug development hurdles 🧪 Lack of reliable biomarkers Now, we’re breaking them down through our three-pronged approach. See how here: bit.ly/4mcUZ4O

At our Annual Meeting, some of the world’s leading minds in #ALSResearch came together to break barriers, spark breakthroughs, and explore what’s possible. 📩 Our Annual Meeting Impact Report drops Monday, and it covers it all. Sign up to get it first: bit.ly/3GGRGTT

We don’t often extend projects to a third year, but when science shows this much promise, we double down. Learn more about the science driving our continued investment: bit.ly/3TJNBBD #ALS #ALSResearch #EveryoneLives

At 26, Leah Stavenhagen was ready to launch her dream career and planning a bright future. Then came an #ALS diagnosis that shattered the life she envisioned, but she didn't retreat. Read her inspiring story, including how she founded #HerALSSstory: bit.ly/4kMfDHI

In collaboration with Biospective, we fund our In Vivo Target Validation Program, an initiative that helps researchers test whether experimental therapies can engage disease targets and modify ALS progression. Meet the 2025 grantees and learn more: bit.ly/4kHAqMs

When Brooke Eby was diagnosed with ALS at 33, she didn’t go quiet; she went public. Now, she leads a movement rooted in storytelling and fueled by hope. Read her story and see why she chose to raise funds for Target ALS during this #ALSAwarenessMonth: bit.ly/4nPNJxh

The breakthroughs shared at our 2025 Annual Meeting reflect something bigger than progress; they reflect possibility. Our Summer Impact Report recaps it all. 📩 Sign up for our emails to get the report straight to your inbox: bit.ly/3GGRGTT #ALSResearch #ALS

Please join us in welcoming Dr. Daniel Weatherill, Data Scientist, to the Target ALS team! With a deep passion for making data meaningful, Dr. Weatherill brings both technical expertise and heartfelt purpose to our mission. We're thrilled to work with him to advance #ALSResearch.

We’re proud to share that we have earned the 2025 Platinum Seal of Transparency from Candid (formerly Guidestar)—the highest honor for nonprofit accountability and transparency. Transparency is essential to accelerating #ALSResearch. Learn more: bit.ly/3GfrbVW

In partnership with PacBio, we’ve launched the largest global whole-genome sequencing initiative for ALS to date — and we recently highlighted this effort in a powerful webinar. Watch a recording to see how it's breakthroughs in #ALSResearch worldwide: bit.ly/3GCOsRx

The average lifespan after an #ALS diagnosis is just 2–5 years, which means research can’t afford to stall, and donated samples can’t sit on a shelf. At Target ALS, we ensure that every donated sample is put to work immediately. See our impact in action: bit.ly/44sfEvm

The Target ALS Data Engine plays a crucial role in accelerating #ALSResearch by making high-value data accessible to scientists worldwide, with no strings attached. Get access to rich, curated datasets without IP restrictions or cost barriers today: bit.ly/4ia7Zpl

Dr. Javier Oroz is using the Target ALS Biofluids Core to advance #ALSResearch by detecting misfolded TDP-43, a protein that becomes toxic in the vast majority of #ALS cases. See how your research can benefit from our no-strings attached resources: bit.ly/4ia7Zpl

Target ALS is funding a bold new wave of therapies aimed at TDP-43 pathology early in the disease process, with the potential to delay or even prevent symptoms. Read how we're taking aim at TDP-43: bit.ly/45ZZDxU #ALS #TDP43 #Neuroscience #EveryoneLives

Our ALS Global Research Initiative is a global movement united in the spirit of #RadicalCollaboration and innovation. With every facet of this effort we’re breaking down barriers to accelerate discovery and bring hope to every corner of the world. bit.ly/3ZRz1eR.

During our Annual Meeting, Dr. Arti Patel from Novartis shared how a global team is pioneering a new way to track #ALS and #FTD. Sign up to see how their insights could pave the way for innovative tests to identify disease. targetals.org/join-us/

Last month, Target ALS was featured by @Intersection_Co on @LinkNYC throughout New York City to celebrate #ALSAwarenessMonth. The campaign featured 5 New Yorkers, including our founder, Dan Doctoroff, who drive #ALSResearch. Read more about the campaign: bit.ly/40dg5Hr

New Funding Opportunity: Springboard Fellowship The Target ALS Springboard Fellowship supports senior lab fellows pursuing careers in #ALS #FTD research transition to an independent academic tenure track or equivalent positions. Apply today: targetals.org/springboard-fe…

At our Annual Meeting, Dr. Jenna Gregory shared how her team is bringing oncology-style precision to ALS—studying how T cells behave differently with #ALS. Her findings, through research we fund, offer clues for better treatment. Sign up to learn more: bit.ly/3GGRGTT

On #GlobalALSMNDAwarenessDay, we reaffirm our commitment to #ALS research without borders. Through AGRI, we’re powering global access to biofluids + data to drive real-time breakthroughs. Join the movement: targetals.org/agri/